Deep Breeze Breakthrough Lets Patients Breathe Better

Around the globe, some 200 million people suffer from chronic obstructive pulmonary disease (COPD), a progressive lung condition usually triggered by long-term smoking. As the disease worsens, patients typically face hospitalization several times a year – at a cost of thousands of dollars per day.

An Israeli company’s innovative medical device could radically change that scenario. Once approved by the US Food and Drug Administration (FDA), the trademarked Breeze@home, will allow COPD and other chronic lung disease patients to stay out of the hospital while receiving continuous remote monitoring by their healthcare provider from home.

“This will not only make life more bearable for them, but will also save the healthcare system a lot of money,” points out Dr. Michael Nagler, CEO of Deep Breeze Continue reading